All In Biotech

Drug Trial Radar · NCT00004205

Letrozole or Tamoxifen in Treating Postmenopausal Women With Breast Cancer

A Phase III Study to Evaluate Letrozole as Adjuvant Endocrine Therapy for Postmenopausal Women With Receptor (ER and/or PgR) Positive Tumors

Last checked: Nov 20, 2026Latest source record: Dec 12, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 8,028 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

8,028

Actual

Start

Mar 1998

Primary completion

Dec 2008

Study completion Jun 30, 2016

Sponsor

Lead sponsor
ETOP IBCSG Partners FoundationResearch network
Sponsor type
Research network
Collaborators
UNICANCER; Danish Breast Cancer Cooperative Group
First posted
Jan 27, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Female only, from 30 years, up to 120 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by reducing the production of estrogen. Hormone therapy using tamoxifen may fight breast cancer by blocking the uptake of estrogen by the tumor cells. If is not yet known which treatment regimen is most effective for breast cancer. PURPOSE: Randomized double-blind phase III trial to compare the effectiveness of letrozole with that of tamoxifen in treating postmenopausal women who have breast cancer that has been surgically removed.

Conditions

  • Breast Cancer

Interventions

  • letrozoleDrug

    Letrozole 2.5 mg daily oral administration.

  • tamoxifen citrateDrug

    Tamoxifen 20 mg daily oral administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease free survival.Time frame: Up to end of year 2015

Locations

3 sites in 3 countries. Site status is shown where the registry gives one.

  • Rigshospitalet

    Copenhagen, Denmark

  • Institut Bergonie

    Bordeaux, France

  • Kantonsspital - St. Gallen

    Sankt Gallen, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.